<DOC>
	<DOCNO>NCT01156844</DOCNO>
	<brief_summary>This study assess bronchodilator efficacy three different regimen indacaterol patient asthma</brief_summary>
	<brief_title>Efficacy , Safety Pharmacokinetics Different Regimens Indacaterol</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Patients diagnosis asthma : Receiving daily treatment inhale corticosteroid regimen stable least month prior screen FEV1 ≥50 % ≤90 % predict normal screen An increase ≥12 % ≥200 mL FEV1 prebronchodilator value within 30 minute inhale total dose albuterol/salbutamol 360/400 MDI Smoking history ≥ 10 year Patients diagnosis COPD Patients previously intubate severe asthma exacerbation/ attack Patients experience severe asthma attack/exacerbation require hospitalization 6 month prior screen Patients emergency room visit asthma attack/exacerbation within 6 week prior screen Patients respiratory tract infection within 6 week prior screen Patients seasonal allergy whose asthma likely deteriorate study period Patients Type I uncontrolled Type II diabetes mellitus Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Indacaterol</keyword>
	<keyword>Asthma</keyword>
	<keyword>Bronchodilation</keyword>
	<keyword>Beta-agonist</keyword>
</DOC>